Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma
Tanguy Y. Seiwert(Georgetown University), Amanda Psyrri(National and Kapodistrian University of Athens), Shunji Takahashi(Japanese Foundation For Cancer Research), Jérôme Fayette(Université Claude Bernard Lyon 1), Myung‐Ju Ahn(Sungkyunkwan University), Katia Real(AstraZeneca (United Kingdom)), Nassim Morsli(Boehringer Ingelheim (France)), Jill Walker(AstraZeneca (United Kingdom)), Anne L’Hernault(AstraZeneca (United Kingdom)), Brent Evans(AstraZeneca (United States)), Jean‐Pascal Machiels(Cliniques Universitaires Saint-Luc), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Valerie L. Baker(Johns Hopkins University), Shrujal S. Baxi(Cambridge Health Alliance), Jared Weiss(Georgetown University), Sophie Wildsmith(AstraZeneca (United Kingdom))
Cited by 9
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k